Abstract

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for Treatment for Patients with Richter Transformation

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Sattva S Neelapu ... Xiaoping Su
Blood | VOL. 138
Sattva S Neelapu, et. al.Sattva S Neelapu ... Xiaoping Su
05 Nov 2021
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results
Michael J Keating ... Alessandra Ferrajoli
Blood | VOL. 138
Michael J Keating, et. al.Michael J Keating ... Alessandra Ferrajoli
05 Nov 2021
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Ryan Jacobs ... Stephen J Schuster
Blood | VOL. 134
Ryan Jacobs, et. al.Ryan Jacobs ... Stephen J Schuster
13 Nov 2019
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Marina Konopleva ...
Blood | VOL. 138
Marina Konopleva, et. al.Marina Konopleva ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study.
Linda Sundler Björkman ... Bengt Zöller
Blood | VOL. -
Linda Sundler Björkman, et. al.Linda Sundler Björkman ... Bengt Zöller
17 May 2024
Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Jennifer A Woyach ... Veerendra Munugalavadla
Blood | VOL. -
Jennifer A Woyach, et. al.Jennifer A Woyach ... Veerendra Munugalavadla
16 May 2024
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Chiara Malinverni ... Carlo Visco
Blood | VOL. -
Chiara Malinverni, et. al.Chiara Malinverni ... Carlo Visco
16 May 2024
Fusion Harboring Mast Cells Can Explain Molecular Positivity in Flow Cytometric MRD Negative Core Binding Factor AML.
Jacqueline A Cook ... Andrew J Menssen
Blood | VOL. -
Jacqueline A Cook, et. al.Jacqueline A Cook ... Andrew J Menssen
15 May 2024
View more papers